Skip to main content
Premium Trial:

Request an Annual Quote

Bruker AXS, Stepping Into New Market, to Acquire X-ray Microanalysis Tool Shop Roentec

NEW YORK, Oct. 14 (GenomeWeb News) - Stepping into a new market, Bruker AXS today said it plans to acquire Roentec, a German X-ray microanalysis instrument company for an undisclosed amount.


Privately held Roentec, based in Berlin, generates between $6 million and $7 million in annual revenues, Bruker said. The deal is expected to close in the fourth quarter.

Bruker claims the worldwide X-ray microanalysis market to be north of $150 million and said it "has not participated" in it. Typical applications of X-ray microanalysis include nanotechnology and "advanced materials research."

Selling its products "primarily" in Europe, Roentec's X-ray microanalysis products are sold with detector technology, acquisition electronics, and analysis and quantification software. The company also sells mobile systems for the X-ray elemental microanalysis of works of art, as well as transportable "Total X-ray Reflection" systems for elemental trace analysis in liquids, according to Bruker.


Roentec CEO Thomas Schuelein said in a statement today that Bruker's global distribution muscle "can ... enhance the revenue growth" for the company's mobile microXRF and TXRF systems.


Frank Burgaezy, executive vice president at Bruker AXS, agreed, saying in the statement that Roentec, though it has "a strong customer base in certain geographical markets, ... has been distribution-limited and at a size disadvantage relative to its larger competitors."


According to Bruker, the X-ray microanalysis market comprises X-ray accessories for scanning and transmission-electron microscopes and stand-alone micro-X-ray fluorescence spectrometers.


Though Bruker AXS plays in the X-ray diffraction space for advanced materials and nanotechnology research, in X-ray single crystal diffraction for small molecule and protein 3D structural analysis, and in X-ray fluorescence elemental analysis for a variety of materials-analysis and quality-control applications, the company has not participated in X-ray microanalysis, which it calls a "fourth important" X-ray analysis market.

News of the acquisition comes almost exactly two months after Bruker AXS said it would buy French X-ray analysis-software company Socabim for an undisclosed sum.


As GenomeWeb News reported in August, Socabim has already been providing software for X-ray diffraction and X-ray fluorescence materials analysis to Bruker AXS. Bruker plans to merge Socabim with its own French subsidiary near Paris.


Socabim employees are expected to remain with the company following the acquisition, which is expected to close in the first quarter of 2006.


"We believe that with the addition of the Socabim technology and R&D   team, our products can accelerate their 'time-to-market,' and our X-ray   systems for advanced research and process analysis [...] will be even more   powerful and user-friendly," Frank Burgazy, managing director of Bruker AXS and president of the French subsidiary, said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.